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GObjective:Accurate pathologic restaging of N2 stations after neoadjuvant therapy in stage IIIA (N2) non–small
cell lung cancer is needed.
Methods: A prospective multi-institutional trial was designed to judge the feasibility of videothoracoscopy to
restage the ipsilateral nodes in mediastinoscopy-proven stage IIIA (N2) non–small cell lung cancer after 2 cycles
of platinum-based chemotherapy and/or 40 Gy or more of radiotherapy. The goals included biopsy of 3 negative
N2 node stations or to identify 1 positive N2 node or pleural carcinomatosis.
Results: Ten institutions accrued 68 subjects. Of the 68 subjects, 46 (68%) underwent radiotherapy and 66
(97%) underwent chemotherapy. Videothoracoscopy successfully met the prestudy feasibility in 27 patients
(40%): 3 negative stations confirmed at thoracotomy in 7, persistent stage N2 disease in 16, and pleural carci-
nomatosis in 4. In 20 procedures (29%), no N2 disease was found, 3 stations were not biopsied because
of unanticipated nodal obliteration. Thus, 47 videothoracoscopy procedures (69%, 95% confidence interval,
57%-80%) restaged the mediastinum. Videothoracoscopy was unsuccessful in 21 patients (31%) because
the procedure had to be aborted (n ¼ 11) or because of false-negative stations (n ¼ 10). Of the 21 failures,
15 were right-sided, and 10 had a positive 4R node. The sensitivity of videothoracoscopy was 67% (95% con-
fidence interval, 47%-83%), and the negative predictive value was 73% (95% confidence interval, 56%-86%)
if patients with obliterated nodal tissue were included. The sensitivity was 83% (95% confidence interval, 63%-
95%) and the negative predictive value was 64% (95% confidence interval, 31%-89%) if those patients were
excluded. The specificity was 100%. One death occurred after thoracotomy.
Conclusions: Videothoracoscopy restaging was ‘‘feasible’’ in this prospective multi-institutional trial and pro-
vided pathologic specimens of the ipsilateral nodes. Videothoracoscopy restaging was limited by radiation and
the 4R nodal station. (J Thorac Cardiovasc Surg 2013;146:9-16)The Cancer and Leukemia Group B (CALGB) 8935 study
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The Journal of Thoracic andtherapy for stage IIIA (N2) non–small cell lung cancer
(NSCLC).1 Mature follow-up data from both the CALGB
8935 study and the Southwest Oncology Group 8805, 2 inde-
pendent, prospective, multi-institutional studies, indicated
thatpatientswith residualN2disease at surgical resection after
induction therapy did not enjoy the same survival as thosewith
effective nodal downstaging.2,3 Specifically, in the Southwest
OncologyGroup 8805 study, a significant differencewas seen
in median survival between those with no N2 nodal disease at
thoracotomy (30months) and thosewith persistentN2 disease
(10 months,P¼ .005).2 Likewise, in the CALGB 8935 study,
the median failure-free survival after a postsurgical 3-month
landmark (to account for heterogenous adjuvant treatments)
was 47.8 months if downstaged to no disease in the N2 nodes
at thoracotomycomparedwith 8.2months if persistent disease
was present (P ¼ .01).3 Such patients rarely benefited from
surgical resection, which sometimes caused perioperative
morbidity, mortality, and temporary loss of independence.
Accordingly, we need a safe, accurate,minimally invasive
method to restage the mediastinal nodes after neoadjuvantCardiovascular Surgery c Volume 146, Number 1 9
Abbreviations and Acronyms
CALGB ¼ Cancer and Leukemia Group B
EBUS ¼ endobronchial ultrasound
EUS ¼ endoesophageal ultrasound
NPV ¼ negative predictive value
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
VATS ¼ videothoracoscopy
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Stherapy to allow the separation of patients expected to ben-
efit from surgical resection from those with persistent nodal
disease. Pathologic restaging of the mediastinal nodes could
prevent futile thoracotomy for those not responding to in-
duction therapy. Repeat mediastinoscopy has been associ-
ated with an increased risk of complications and reduced
accuracy because the paratracheal spaces, subcarinal space,
and aortopulmonarywindow are fused after previous dissec-
tion, radiotherapy, or cytotoxic therapy.4,5
Thoracoscopy is an attractive alternative to repeat media-
stinoscopy because of its enhanced visibility and access to
the posterior mediastinal, inferior mediastinal, retrohilar,
and aortopulmonary window nodes. Although thoraco-
scopy can also discover clinically occult pleural carcinoma-
tosis, it limits the surgeon to an ipsilateral assessment of the
mediastinum.
Our hypothesis was that thoracoscopy could be used to
provide pathologic restaging of the ispislateral nodes after
neoadjuvnat therapy in those patients proved to have path-
ologic involvement of those nodes before treatment. Our
primary endpoint was to determine the safety and feasibility
of accessing multiple nodal stations thoracoscopically and
to validate apparent downstaging with thoracotomy. If the
technique of thoracoscopic restaging can be validated in
the present feasibility study, the concept could become an
important piece of the future strategy of CALGB activity,
as multimodality therapy for stage III NSCLC is refined.
METHODS
A prospective, nonrandomized phase II trial was designed to evaluate
the feasibility of videothoracoscopy (VATS) to assess resectability in pa-
tients with stage IIIA (N2) NSCLC after previous mediastinoscopy and
neoadjuvant therapy by the CALGB group, a National Cancer Institute-
sponsored multi-institutional cooperative group. Unresectability was
defined as the presence of a persistently positive mediastinal (N2) lymph
node or pleural carcinomatosis. Secondary objectives included documenta-
tion of safety and assessment of the accuracy (false-negative rate) of prere-
section thoracoscopic mediastinal node restaging after previous
mediastinoscopy and induction therapy.
Eligibility required histologic documentation of stage IIIA (N2) by
mediastinoscopy performed before induction therapy. At least 2 cycles of
chemotherapy with or without radiotherapy (40 Gy) or radiotherapy
alone (40 Gy) had to be completed within 60 days of registration. Patients
with responding or stable local disease were eligible.
Patients were ineligible for the present trial if they had a comorbid
illness that made them unsuitable for subsequent resection, if they were10 The Journal of Thoracic and Cardiovascular Surgeunwilling to undergo subsequent anatomic resection (ie, lobectomy or
pneumonectomy), had postinduction spirometry, which suggested they
could not undergo surgery, or had a currently active second malignancy
other than a nonmelanoma skin cancer. Patients with previously treated re-
lapsed lung cancer were not eligible. Those with local disease progression,
defined as a 25% increase in local tumor size or the appearance of new
areas of malignant disease, were also ineligible. The patients could not
have a history of intrapleural surgery on the ipsilateral side. An Eastern
Cooperative Oncology Group performance status of 0 to 2 was required.
All patients provided informed consent, and the individual institutional
review board at each participating institution approved the study. Before
registration, the patients had to be evaluated by a CALGB credentialed tho-
racic surgeon and be determined suitable for surgical resection of their can-
cer. The surgeons were considered credentialed if they had accrued patients
to previous CALGB VATS protocols. New surgeons were credentialed by
the principal investigator after submitting the operative notes of 10 mini-
mally invasive procedures that reflected a skill level necessary to partici-
pate in the present protocol.
Before making the thoracotomy incision to resect the lung after neoad-
juvant therapy, patients underwent ipsilateral VATS. The patient was posi-
tioned in a lateral decubitus position after selective lung ventilation was
established. Three to four thoracoscopic ports were recommended,
although the placement of ports was left to surgeon discretion. In general,
the camera port was placed in the 6th or 7th intercostal space, and the pleu-
ral space was evaluated for adhesions. Additional operative ports were rec-
ommended to be in line with the planned thoracotomy incision, including 1
anterior to the scapular tip and 1 at the posterior extent. A fourth port, if
needed, was generally placed in the axilla.
Thoracoscopic restaging was considered positive if histologic proof was
present of pleural carcinomatosis, malignant effusion, or any positive me-
diastinal node. The diseased nodal station identified by pretreatment
mediastinoscopy was a specific target for restaging, unless pleural carcino-
matosis or another positive mediastinal nodal station was identified before
sampling that particular station. The procedure was considered complete
and negative if no evidence was found of unresectability, at least 3 nodal
stations were sampled, and no evidence of malignant disease was found.
The protocol guided the surgeon to restage specific nodal stations as
a function of the primary tumor location. Tumors in the right upper lobe
were to have stations 2R, 4R, and 7 sampled. Tumors of the right middle
and right lower lobes were to have biopsy samples taken of stations 4R,
7, and 9R, and samples of station 2R were encouraged but optional. Right
hilar tumors were to have samples from stations 2R, 4R, 7, and 9R. Left
upper lobe tumors were to have biopsy samples of stations 5, 6, and 7
and samples of station 4L were encouraged ‘‘if feasible’’ (wording of the
protocol). Left lower lobe tumors were to be restaged by sampling stations
5, 7, 9L, and biopsy samples of station 4L were optional. Likewise, left
hilar tumors were to have biopsy samples of stations 5, 6, 7, or 9L, with
optional sampling of station 4. At thoracotomy, these same nodal stations
were to be sampled. In particular, the original positive nodal station iden-
tified at pretreatment cervical mediastinoscopy was a specific target at
thoracotomy.
Most patients with negative restaging findings underwent thoracotomy
and anatomic resection (ie, lobectomy, bilobectomy, or pneumonectomy)
with mediastinal lymphadenectomy under the same anesthetic. Seven pa-
tients underwent VATS restaging and thoracotomy as 2 separate proce-
dures. The interval ranged from 6 to 29 days. Patients with positive
restaging findings could still undergo resection at the discretion of the
surgeon.Statistical Considerations
Patient registration and data collection were managed by the CALGB
Statistical Center. Data quality was ensured by CALGB Statistical Center
staff and by the study chair. Statistical analyses were performed by CALGB
statisticians using SAS, version 9.1 (SAS Institute Inc, Cary, NC).ry c July 2013
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tinal (N2) lymph node stations or to identify 1 positive mediastinal lymph
node or pleural carcinomatosis. This feasibility protocol ended at the com-
pletion of surgery with either the finding of persistent malignancy or suc-
cessful surgical resection. Long-term survival and recurrence patterns
were not endpoints of the present study.
At the outset of the study, it was agreed that additional development of
the surgical technique would be of interest if greater than 80% of patients
had a successful procedure; additional investigation of the techniquewould
not be warranted if fewer than 65% had a successful procedure unless sig-
nificant modifications were done. With a planned accrual of 75 patients,
there would be 90% power to differentiate a true feasibility rate of 65%
versus 80% at a 1-sided significance level of .05.
The feasibility rate of VATS restaging and its 95% confidence interval
(CI) are provided. The sensitivity and specificity of VATS restaging were
calculated with the outcome of thoracotomy as the reference standard.
The negative predictive value (NPV) and positive predictive value of
VATS restaging were also calculated. All reported P values are 2 sided.
Grade 3 and greater complications were tabulated. The potential variables
influencing VATS restaging success were evaluated using logistic regres-
sion analysis.RESULTS
From activation on September 15, 1998, to closure on
September 30, 2003, the accrual target was met by 75 par-
ticipants from 10 institutions. Seven patients were unevalu-
able. Three subjects had undergone positron emission
tomography (PET) staging of IIIA (N2) disease only, with-
out pretreatment mediastinoscopy. The other 4 reasons
(1 each) were a change in the postresection pathologic iden-
tification of hemangioendothelioma instead of lung cancer,
a positivemediastinoscopy node that proved to be contralat-
eral N3 disease and not an ipsilateral N2 mediastinal node
(thus providing no pretreatment target to restage), PET stag-
ing without mediastinoscopy before neoadjuvant treatment
(thus no pathologically confirmed target for restaging), and
bulky hilar disease with direct invasion into the mediasti-
num that precluded subsequent surgical resection. The sub-
sequent analysis was based on the data from 68 patients
(Figure 1).
The demographic data are summarized in Table 1. Most
participants were white, and 49% were men. The median
age of this cohort was 61 years (range, 40-77 years). The
Eastern Cooperative Oncology Group performance status75 enrolle
68 evalua
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FIGURE 1. Flow sheet
The Journal of Thoracic and Cwas 0 in 60% and 1 in 40%. All patients had undergone ei-
ther neoadjuvant chemotherapy (97% received1 cycle of
chemotherapy, and 49% received 3 cycles) or radiotherapy
(68%), or both, before enrollment. About one half (49%) of
the participants were diagnosed with adenocarcinoma. Of
the 68 patients, 53 (78%) had just 1 positive mediastinal
nodal station on initial mediastinoscopy, 14 (21%) had 2
positive N2 nodal stations, and 1 (1%) had 3 positive N2
nodal stations. Thus, 15 of the 68 (22%) evaluable partici-
pants had multistation N2 disease; a population that many
would not consider for resection outside of an investiga-
tional protocol.
Thoracoscopic restaging was performed on the right side
in 75% of the participants. The median number of thoraco-
scopic incisions was 3 (range, 1-4). The median duration
of the VATS restaging procedure was 63 minutes (range,
15-313 minutes). Thoracotomy was performed in 61 pa-
tients. The 4 patients found to have pleural carcinomatosis
and 3 of those found to have persistent nodal disease did
not undergo subsequent thoracotomy.
Postoperative morbidity data were available for 66 pa-
tients and are summarized in Table 2. One operative death
(only case of grade 5 toxicity) occurred in the present study
of acute respiratory distress syndrome after subsequent tho-
racotomy for lung resection. A total of 9 individual grade 3
toxicities were noted in 7 patients after a combination of
thoracoscopic restaging followed by thoracotomy and
attempted anatomic resection. One patient experienced
a biopsy forceps injury to the left main bronchus (grade 3
toxicity) during restaging of the station 7 subcarinal nodes.
The restaging procedure was abandoned in this patient, and
thoracotomy was performed to repair the recognized injury.
A grade 4 cardiovascular arrhythmia and a grade 4 thrombo-
sis occurred in the same patient who died of acute respira-
tory distress syndrome (grade 5).
The median interval with a chest tube in place was 4 days
(range, 1-72 days). Prolonged chest tube duration was at-
tributed to air leaks from the anatomic resection in 88%
of evaluable patients with stage IIIA disease (all of whom
had undergone neoadjuvant therapy) rather than from the
restaging procedure.d 7 ineligible
ble
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TABLE 1. Patient demographic and baseline clinical characteristics
(n ¼ 68)
Variable Value
Gender
Male 33 (49)
Female 35 (51)
Age (y)
Median 61
Range 40-77
Race
White 66 (97)
Black 1 (1)
Asian 1 (1)
Performance status
0 41 (60)
1 27 (40)
Previous treatment
Thoracic radiotherapy 46 (68)
Induction chemotherapy 66 (97)
Initial diagnosis
Adenocarcinoma 33 (49)
Squamous cell carcinoma 16 (24)
Undifferentiated large cell carcinoma 2 (3)
Undifferentiated non–small cell carcinoma 17 (25)
Positive nodes on mediastinoscopy (n)
1 53 (78)
2 14 (21)
3-4 1 (1)
Data presented as n (%), unless otherwise noted.
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VATS restaging met the prestudy criteria of feasibility in
27 of the 68 eligible cases (40%). This group included 7
(10%) restaging procedures that successfully sampled 3
negative mediastinal nodal stations, confirmed by absentTABLE 2. Thoracic surgical complications (n ¼ 66)
Complication
Toxicity grade (n)
3 (Severe)
4 (Life
threatening)
5
(Lethal)
Cardiovascular (arrhythmia)
Arrhythmia, other 2 (3) 1 (2) 0
Supraventricular arrhythmias 3 (5) 0 0
Cardiovascular (general)
Thrombosis/embolism 0 1 (2) 0
Operative injury of bronchus 1 (2) 0 0
Dermatology/skin
Wound infection 1 (2) 0 0
Pulmonary
Adult respiratory distress
syndrome
0 0 1 (2)
Pneumothorax 1 (2) 0 0
Pulmonary, other 1 (2) 0 0
Total patients with toxicity 7 (11) 1 (2) 1 (2)
Data in parentheses are percentages. Only grade 3 and greater surgery-related
complications listed.
12 The Journal of Thoracic and Cardiovascular Surgeresidual nodal disease at thoracotomy (including the origi-
nally diseased nodal stations discovered at mediastino-
scopy), 16 participants (24%) who had 1 or more
persistently positive mediastinal nodes sampled before tho-
racotomy, and 4 patients (6%) with clinically occult pleural
carcinomatosis (T4 disease).
Of the 68 subjects, 21 (31%) did not have a successful
VATS restaging procedure. The procedure was aborted in
11 owing to pleural space adhesions or tumor bulk
(n¼ 9), injury to the airway (n¼ 1), or an inability to achieve
adequate atelectasis (n¼ 1). In 4 patients, 3 lymph node sta-
tions had biopsy cores taken thoracoscopically without evi-
dence of tumor, but residual nodal disease was found at
thoracotomy. Finally, fewer than 3 lymph node stations
were sampled thoracoscopically with obliterated nodal sta-
tions and no nodal disease found by VATS restaging but
N2 disease found at thoracotomy in 6. These were consid-
ered VATS restaging failures. We could detect no statistical
relationship between the primary tumor locations (upper vs
lower lobe) or surgeon restaging experience and the likeli-
hood of having a failed or inadequately sampled outcome.
In 26 patients (38%), the prestudy success endpoint
failed because fewer than 3 nodal stations had biopsy sam-
ples taken during restaging. Despite dissection of these
mediastinal N2 stations by experienced surgeons during
thoracotomy and lung resection, no nodal tissue was identi-
fied in at least 1 N2 station for each of these patients. The
neoadjuvant chemotherapy and/or radiotherapy appeared
to have obliterated all nodal tissue within the anatomic
station, and only scar tissue remained. Of these 26 cases,
6 were mentioned in the previous paragraph as being
a false-negative sampling of persistent nodal disease found
at thoracotomy and were included in the VATS restaging
failure group.
The remaining 20 subjects (29% of the evaluable group)
had a positivemediastinal node atmediastinoscopy, received
neoadjuvant therapy, and had at least 1 nodal station with no
remaining nodal tissue, but no nodal disease was found at
thoracotomy with nodal dissection. Of these 20 patients,
a VATS biopsy of the originally positive nodal stations was
obtained in 14 patients (70%), but a third nodal station had
no nodal tissue. None of these 20 subjects had nodal disease
found at the original site at thoracotomy, confirming down-
staging of the disease. Because neoadjuvant therapy obliter-
ated at least 1 required nodal station, the prestudy definition
of success was flawed, because it was impossible to attain in
somecases.Accordingly, itwouldbe reasonable to reclassify
these 20 cases as a part of a separate analysis.
Using these data, if the subgroup of participants with inad-
equate sampling were considered a VATS failure, the feasi-
bility rate would be 27 of 68 or 40% (95% CI, 28%-52%)
and the false negative rate (VATS did not detect persistent
nodal disease discovered at thoracotomy) would be 38.5%
(95% CI, 20%-59.4%). If the subgroup of patients withry c July 2013
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tent nodal disease was present at thoracotomy were consid-
ered VATS successes, the feasibility rate would be
(20 þ 27)/68 or 69% (95% CI, 57%-80%), with a false-
negative rate of 33% (95% CI, 17%-53%). Because the
estimated feasibility rate of 69% is greater than the prespeci-
fied lower limit of continued interest (ie, 65%), the feasibility
ofVATS restaging remains a question of interest for future in-
vestigation. However, because the lower limit of continued
interest lies within the 95% CI of 57% to 80%, our data
failed to unequivocally establish the feasibility of VATS
restaging.
Effects of Radiotherapy and Chemotherapy
Logistic regression analyses were conducted to examine
the effect of radiotherapy (received vs not received) on
VATS efficacy (success vs failure, and success vs empty
nodal stations with negative thoracotomy). The analysis in-
dicated that VATS failure using the prestudy definitions was
associated with radiotherapy (Tables 3 and 4), although this
was not dose related. Also, no statistically significant differ-
ence was found in the efficacy between the groups receiving
0 to 2 cycles of chemotherapy compared with those partic-
ipants receiving greater than 2 cycles. In addition to the
radiation effect, patients with adenocarcinoma had a signif-
icantly lower chance of VATS success than did patients with
other histologic types.
Anatomic Correlation With Restaging Failure
An analysis of the location of persistently positive medi-
astinal nodes found at thoracotomy when the VATS restag-
ing procedure failed to detect positive nodes is presented in
Table 5. Nearly one half of all the false-negative nodes were
in station 4R.
DISCUSSION
The results of the present study have demonstrated that
VATS could be a useful tool to detect or exclude persistent
nodal disease, and VATS restaging might have a superior
NPV in patients who do not receive radiotherapy as a part
of their induction therapy. It proved particularly useful inTABLE 3. VATS outcome stratified by receipt of radiotherapy or
chemotherapy (n ¼ 64*)
VATS outcome Patients (n)
Radiation dose (cGy) None <5000 5000-<6000 60,000
Success 11 5 5 2
Failure 5 6 6 4
Inadequate sampling 5 9 3 3
Chemotherapy cycle None 1-2 3-5 6-8
Success 1 8 10 4
Failure 0 8 7 6
Inadequate sampling 0 16 4 0
VATS, Videothoracoscopy. *Four patients with pleural carcinomatosis not included.
The Journal of Thoracic and Cdiscovering occult pleural carcinomatosis (6% in the pres-
ent prospective trial) after neoadjuvant therapy for IIIA
(N2) disease. Restaging thoracoscopy did have trouble reli-
ably restaging the station 4R nodes.
Neoadjuvant therapy before surgical resection of locally
advanced stage IIIA (N2) NSCLC improves survival for
those patients who have had sterilization of their mediasti-
nal nodes.2,3 More specifically, patients with persistent N2
disease at surgical resection have long-term survival similar
to that of those treated nonoperatively.6 Mature analyses of
both the Southwest Oncology Group 8805 study2 and
CALGB 8935 trial3 showed that nodal downstaging is the
most important predictor of long-term survival.
The mediastinal nodal downstaging rate of 21% to 50%
seen in the 2 American Cooperative Group trials and the
clinical significance of persistent disease emphasize the
need to accurately restage the mediastinum after neoadju-
vant therapy. Imaging alone has been unable to provide suf-
ficient accuracy. Although PET scans have shown value in
predicting persistent viable tumor in the primary tumor
bed, they are unreliable in assessing the mediastinal nodes.
The specificity for persistent mediastinal nodal disease in
restaging PET scans has generally been 85% to 90%, but
the sensitivity has been disappointingly low at 50% to
60%.7-12 This might be because of the inability to detect
a small focus of persistent disease within fibrosis or
altered perfusion to the nodes that affect the PET tracer.
The inability to accurately predict persistent nodal dis-
ease by noninvasive imaging has led to the use of surgical
restaging of the mediastinum. Although some investigators
have reported an accuracy for repeat mediastinoscopy
approaching that of initial mediastinoscopy,13,14 other
large series have reported lower sensitivity and accuracy
rates. A series of 104 repeat mediastinoscopies from 2
European academic centers in Spain and Belgium
reported a sensitivity of 71%, specificity of 100%, and
accuracy of 84%. That series also reported a 2% rate of
massive hemorrhage (1 aortic arch and 1 superior vena
cava) and 1% mortality.5 A second combined German se-
ries of 104 repeat mediastinoscopies reported a sensitivity
of 61% and accuracy of 88%.15 A prospective trial compar-
ing the accuracy of repeat mediastinoscopy and PET-
computed tomography fusion scans in 30 patients reported
that the repeat surgical procedure was technically feasible
but inaccurate owing to severe adhesions and fibrosis.7
The sensitivity to detect residual mediastinal disease in
the present study was only 29%, with an accuracy of
60%. Fibrosis not only affects the accuracy of a repeat pro-
cedure, but also negatively affects the completeness of the
mediastinal evaluation.4
It was unanticipated at the present trial’s design that the
use of high-dose neoadjuvant chemotherapy and radiother-
apy would become widespread. The recognition that com-
plete obliteration of all nodal tissue within a station of theardiovascular Surgery c Volume 146, Number 1 13
TABLE 4. Statistics of logistic regression analysis of radiotherapy or chemotherapy on VATS success
Variable
Success vs failure Success vs inadequate sampling
P value OR (95% CI) P value OR (95% CI)
Radiotherapy (none vs yes) .0525 4.9 (1.0-24.6) .0404 5.4 (1.1-26.6)
Age .8226 1.0 (0.9-1.1) .4116 0.9 (0.8-1.0)
Gender (male vs female) .1731 0.4 (0.1-1.5) .2178 0.4 (0.1-1.7)
Histologic type (adenocarcinoma vs other) .0267 5.6 (1.2-25.6) .0349 4.9 (1.1-21.1)
Chemotherapy (2 vs>2 cycles) .7544 0.8 (0.2-3.4) .0059 0.1 (0-0.5)
Age .7428 1.0 (0.9-1.1) .6509 1.0 (0.9-1.1)
Gender (male vs female) .1068 0.3 (0.1-1.3) .3872 0.5 (0.1-2.3)
Histologic type (adenocarcinoma vs other) .0598 3.8 (0.9-15.6) .0273 7.2 (1.2-41.4)
‘‘Success’’ defined as meeting protocol endpoints (ie, disease found in pleura, disease in mediastinal node, or 3 nodal stations sampled without disease); ‘‘failure’’ defined as not
meeting protocol endpoints (ie, biopsy samples not obtained from 3 negative nodal stations or procedure aborted); ‘‘inadequate sampling’’ indicates inability to sample 3 nodal
stations secondary to obliteration of nodal tissue. VATS, Videothoracoscopy; OR, odds ratio; CI, confidence interval.
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therapy is 1 of the contributions of the present study. Twenty
patients (nearly one third of the evaluable group) had histo-
logically proven N2 disease at initial mediastinoscopy, with
subsequent obliteration of all nodal tissuewithin that station
at both VATS restaging and thoracotomy. Thus, we were
compelled to perform a dual statistical analysis for the 26
participants (39%) within this category. If we accepted
the original protocol criteria that this subgroup would be
defined as VATS failure for inadequate node sampling, the
feasibility rate would only be 39.7%. If we were willing
to consider that this subgroup should be defined VATS suc-
cess because no nodal disease was found at thoracotomy,
the feasibility rate would be 69.1%, which is marginally
feasible. A subset analysis revealed that radiotherapy was
linked to a lack of nodal tissue found within the fibrosis
of these stations, although it was not dose related. Addi-
tional subset analysis also revealed a disproportionate rate
of VATS failure in the station 4R position. Several causes
for this outcome are possible, including the bulk of tumor
being in the right upper lobe, preventing exposure of the
4R position; the relationship of the azygous–caval junction
and the pulmonary artery to the nodal bed; the scar from the
previous mediastinoscopy; and the radiation field effect on
that location.
The strengths of the present prospectivemulti-institutional
surgical studywere considerable. All participants underwent
pretreatment cervical mediastinoscopy with histologicallyTABLE 5. Nodal stations when VATS negative and thoracotomy
positive
Side Station n
Right 2 Upper paratracheal 2
4 Lower paratracheal 10
7 Subcarinal 3
Left 5 Aortopulmonary 4
6 Anterior mediastinal 1
9 Pulmonary ligament 1
VATS, Videothoracoscopy.
14 The Journal of Thoracic and Cardiovascular Surgeconfirmed N2 (not N3) disease by a CALGB thoracic sur-
geon. Neoadjuvant treatment was then set by each individual
institution,withminimal criteria set by the protocol. Also, all
participating surgeons underwent a quality assurance creden-
tialing process.
The present trial also had weaknesses. The original trial
design was created before our recognition that high-dose
neoadjuvant therapy can completely obliterate all nodal tis-
sue at certain stations. This placed us in a position of per-
forming a post hoc analysis of the procedure because of
the impossibility of sampling a node that no longer existed.
Thus, the true feasibility likely lies somewhere between the
2 extremes of the data analysis we presented: the analysis by
the original trial design (missing nodal tissue is failure) and
the analysis by the assumption that missing nodal tissue
could be considered equivalent to a sterilized nodal biopsy.
The possibility of bias exists. If a surgeon failed to find
nodal tissue during the thoracoscopic dissection of an N2
nodal station, it might have influenced the degree of surgical
resection of the same nodal station at thoracotomy and lung
resection. Considering the level of thoracic surgical exper-
tise at the 10 participating centers, this seems unlikely. It is
important to remember that 68 participants limited the
power of the subanalysis. Also, our study was dominated
by right-sided procedures (76%). That limited observations
of the technique on the left, but did allow us to further char-
acterize the problem with sampling the station 4R position.
Finally, the accrual of patients ended in 2003, and staging
and restaging technology has improved since then. How-
ever, we believe the results from the present prospective
trial still provide valuable data to thoracic surgeons who
seek to individualize treatment of patients with stage IIIA
(N2) NSCLC.
The technology has continued to advance since the period
of the present prospective study. Many centers have now
gained experience with minimally invasive endoscopic
techniques such as transbronchial needle aspiration, endoe-
sophageal ultrasound (EUS)-fine needle aspiration, and
endobronchial ultrasound (EBUS)-fine needle aspiration.ry c July 2013
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bronchial needle aspiration samples without neoadjuvant
therapy was 71% and 73%, respectively.16 The accuracy
was greatest in the station 4R position and least in the left
paratracheal position. Although no large prospective studies
have been published using EBUS specifically for restaging
the mediastinum after neoadjuvant therapy for stage IIIA
(N2) NSCLC, data are available for EUS. EUS-fine needle
aspiration has been used to restage 19 patients treated with 3
cycles of platinum-based neoadjuvant chemotherapy with-
out radiotherapy.17 The positive predictive value, NPV, sen-
sitivity, specificity, and diagnostic accuracy was 100%,
67%, 75%, 100%, and 83%, respectively. Another 128-
patient EBUS restaging series, however, showed a NPV of
only 20%.18 Another large series using EUS to stage
untreated mediastinal nodal disease reported a sensitivity
of only 72.6%,19 and a meta-analysis of this same disease
group reported a pooled sensitivity of 83%, with a lower
sensitivity of 39% to 75% for normal-size nodes.20 Needle
samples from fibrotic nodes after high-dose chemoradio-
therapy would likely have even lower sensitivity.
Alternatively, a potential strategy could involve using a non-
invasive technique such as EBUS/EUS at diagnosis and
then saving mediastinoscopy for restaging after induction
therapy. This might also allow the surgeon to assess the
higher and contralateral nodes in a ‘‘virgin’’ mediastinum.
CONCLUSIONS
Thoracoscopic restaging of the mediastinum after neoad-
juvant chemotherapy or radiotherapy is feasible in a pro-
spective multi-institutional setting, although the feasibility
decreased with radiotherapy or attempts to sample the 4R
nodal station. This suggests that thoracoscopy could likely
be combined with other new surgical staging techniques.
EBUS and EUS could likely be used as an initial restaging
modality guided by the results of a repeat PET-computed to-
mography scan. Patients found to have histologic confirma-
tion of mediastinal nodes using these endoscopic
procedures could then undergo additional nonoperative
therapy. Those patients with negative mediastinal node bi-
opsies would then have additional histologic confirmation
of mediastinal nodal sterilization and the lack of pleural car-
cinomatosis by ipsilateral thoracoscopic restaging. Again,
positive nodal disease might be treated nonoperatively.
Thoracotomy and surgical resection might be offered to
those patients with negative needle restaging followed by
negative thoracoscopic restaging. Although intuitive, this
restaging plan would need confirmation in an additional
prospective randomized trial.
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